USANew treatments and approvals
Pegzilarginase, which lowers blood arginine in arginase 1 deficiency, approved in the USA
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The US Food and Drug Administration (FDA) approved pegzilarginase for arginase 1 deficiency. The drug is used to lower high arginine levels in the blood. The approval covers children aged 2 years and older and adults. The treatment is given together with a protein-restricted diet.
What does it mean for patients and families?
This approval applies only in the USA. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with your metabolic disease specialist.
Source
ABD Gıda ve İlaç Dairesi (FDA): Novel Drug Approvals for 2026
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Arginase deficiency (argininemia)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.